Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arena Pharmaceutical (ARNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Arena Pharmaceuticals Announces Changes to Board of Directors

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced Scott H. Bice, Phillip M. Schneider, and Christine A. White, M.D. have indicated that they will be retiring from the Board of Directors at the...

ARNA : 41.87 (+3.33%)
Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS

NEW YORK, NY / ACCESSWIRE / February 9, 2018 / U.S. markets continued to plunge alongside rising interest rates on Thursday. The Dow Jones Industrial Average dropped 4.15 percent to close at 23,860.46,...

VVUS : 0.46 (-4.17%)
ARNA : 41.87 (+3.33%)
Arena Pharmaceuticals to Present at Upcoming Investor Conferences

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that that members of its senior management team will present at two upcoming investor conferences in New York City.

ARNA : 41.87 (+3.33%)
Analysis: Positioning to Benefit within Alliqua BioMedical, Donegal Group, QAD, ManpowerGroup, Acorda Therapeutics, and Arena Pharmaceuticals -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliqua BioMedical, Inc. (NASDAQ:ALQA),...

ALQA : 1.73 (-1.70%)
QADA : 44.30 (+2.78%)
ARNA : 41.87 (+3.33%)
DGICA : 16.61 (+1.28%)
MAN : 123.43 (+1.37%)
ACOR : 26.25 (+3.75%)
This Morning's Technical Outlook on Biotech Stocks -- Arena Pharma, Arrowhead Pharma, Axovant Sciences, and Biogen

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ARNA, ARWR, AXON, and BIIB which can be accessed for free by signing up to www.wallstequities.com/registration....

ARWR : 5.71 (+1.06%)
AXON : 1.64 (-1.20%)
ARNA : 41.87 (+3.33%)
BIIB : 290.20 (+0.96%)
Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City

SAN DIEGO , Jan. 22, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it will host a key opinion leader (KOL) event for investors focused on sphingosine-1-phosphate...

ARNA : 41.87 (+3.33%)
Orexigen Struggles as Contrave Commercialization Costs Rise

Orexigen (OREX) hurt by higher commercialization costs related to Contrave.

OREX : 1.19 (+21.43%)
NVO : 52.15 (+2.27%)
VVUS : 0.46 (-4.17%)
ARNA : 41.87 (+3.33%)
Kaplan Fox & Kilsheimer LLP Announces Proposed Settlement in the Arena Securities Litigation

The following statement is being issued by Kaplan Fox & Kilsheimer LLP regarding the Arena Securities Litigation.

ARNA : 41.87 (+3.33%)
Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the 36th Annual J.P. Morgan Healthcare...

JPM : 117.22 (+2.19%)
ARNA : 41.87 (+3.33%)
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and Everest Medicines Limited ("Everest"), a...

ARNA : 41.87 (+3.33%)
Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Arena Pharmaceuticals, Inc....

NAV : 40.39 (+2.28%)
CFFN : 12.85 (+0.74%)
FIX : 41.35 (+1.85%)
ARNA : 41.87 (+3.33%)
NATI : 50.76 (+2.77%)
NFG : 50.11 (+0.95%)
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.

LGND : 159.23 (+2.39%)
ARNA : 41.87 (+3.33%)
ABBV : 120.45 (+2.09%)
PFE : 36.47 (+1.28%)
Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that it has completed full enrollment in the etrasimod Phase 2 study in ulcerative colitis (UC). Etrasimod is an investigational-stage, oral,...

ARNA : 41.87 (+3.33%)
American Girl's Brand-New Flagship Store To "Rock The Block" At 75 Rockefeller Plaza November 11!

MIDDLETON, Wis. , Nov. 10, 2017 /PRNewswire/ -- Start spreading the news! On November 11 , American Girl Place New York —one of the city's hottest destinations for girls and their families—is...

MAT : 17.19 (+4.37%)
ARNA : 41.87 (+3.33%)
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat

Arena Pharmaceuticals (ARNA) reports another quarter of lackluster Belviq sales. However, the company is likely to advance ralinepag in phase III study based on positive data from the previous stage.

LGND : 159.23 (+2.39%)
EBS : 50.45 (+3.76%)
ARNA : 41.87 (+3.33%)
EXEL : 29.61 (+2.71%)
Biotech Stocks on Investors' Radar -- Aralez Pharma, Arena Pharma, Arrowhead Pharma, and AveXis

If you want a Stock Review on ARLZ, ARNA, ARWR, or AVXS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, November 07, 2017, US markets saw...

ARLZ : 1.66 (+1.84%)
ARWR : 5.71 (+1.06%)
ARNA : 41.87 (+3.33%)
AVXS : 119.06 (+4.93%)
Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), today provided a corporate update and reported financial results for the third quarter ended September 30, 2017.

ARNA : 41.87 (+3.33%)
Arena Pharmaceuticals to Present at the Credit Suisse Healthcare Conference on November 8

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Kevin R. Lind, the Company's Executive Vice President and Chief Financial Officer, will present a corporate update at the 26th Annual Credit...

ARNA : 41.87 (+3.33%)
What's in the Cards for Arena (ARNA) This Earnings Season?

Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.

AGEN : 4.89 (+4.04%)
CLVS : 56.00 (+4.26%)
ARNA : 41.87 (+3.33%)
ACAD : 31.26 (+0.68%)
Arena Pharmaceuticals to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7

SAN DIEGO , Oct. 30, 2017 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced that the Company will release its third quarter 2017 financial results and provide a corporate...

ARNA : 41.87 (+3.33%)

Van Meerten Stock Picks

Nvidia - My Favorite S\&P 500 Large Cap Stock
$NVDA Summary96% technical by signals.
NVDA -2.65
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 unch) this morning are down -0.05% and European stocks are down -0.57% after European manufacturing activity slowed more than expected this month. Losses were contained as the 10-year... Read More

Chart of the Day

Match Group Inc CS (MTCH)

Match Group (MTCH) is the Barchart Chart of the Day.  The popular on-line dating company has a Trend Spotter buy signal, a Weighted Alpha of 190.79+ and gained 152.84% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures are showing fractional gains at Wednesday’s midday. The weekly EIA report will be delayed until Thursday morning, due to Monday’s holiday. Ahead of the USDA Ag Outlook Forum, a Reuters survey of analysts shows expectations fo...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.